Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
ImmuniQ has developed a method for quantifing the actual and functional tumor response to immunotherapy drugs. The company’s immune checkpoint artificial reporter (IcAR) technology is able to quantify binding and shows the actual surface activity of the patient’s cancer cells, enabling more effective treatment for each patient.